Aline Jatho

Aline Jatho


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in Circulation Research
Verified
Journal Article
Open access
PDF file
AJAline Jatho
Aline Jatho
AZAnke Zieseniss
Anke Zieseniss
KBKatja Brechtel-Curth
Katja Brechtel-Curth
AYAtsushi Yamamoto
Atsushi Yamamoto
MCMathew L. Coleman
Mathew L. Coleman
DKDörthe Katschinski
Dörthe Katschinski

21 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
AJAline Jatho
Aline Jatho
AZAnke Zieseniss
Anke Zieseniss
KBKatja Brechtel-Curth
Katja Brechtel-Curth
JGJia Guo
Jia Guo
Kai Oliver BökerKai Oliver Böker
Kai Oliver Böker
DKDörthe Katschinski
Dörthe Katschinski
Inhibition of the prolyl-4-hydroxylase domain (PHD) enzymes, leading to the stabilization of hypoxia-inducible factor (HIF) α as well as to the stimulation of erythropoietin (Epo) synthesis, is the functional mechanism of the new anti-anemia drug roxadustat. Little is known about the effects of roxadustat on the Epo-producing cell pool. To gain further insights into the function of PHD inhibitors, we characterized the abundance of mesenchymal stem cell (MSC)-like cells after roxadustat treatment of mice. The number of Sca-1+ mesenchymal cells following roxadustat treatment increased exclusively in the kidneys. Isolated Sca-1+ cells demonstrated typical features of MSC-like cells, including adherence to tissue culture plates, trilineage differentiation potential, and expression of MSC markers. Kidney-derived Sca-1+ MSC-like cells were cultured for up to 21 days. Within the first few days in culture, cells stabilized HIF-1α and HIF-2α and temporarily increased Epo production upon incubation in hypoxia. In summary, we have identified a Sca-1+ MSC-like cell population that is involved in renal Epo production and might contribute to the strong anti-anemic effect of the PHD inhibitor roxadustat.

27 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
PWPamina Weber
Pamina Weber
DBDoris Baltus
Doris Baltus
AJAline Jatho
Aline Jatho
ODOliver Drews
Oliver Drews
LZLaura C. Zelarayan
Laura C. Zelarayan
SLSusanne Lutz
Susanne Lutz
The Rho guanine nucleotide exchange factor RhoGEF17 was described to reside in adherens junctions (AJ) in endothelial cells (EC) and to play a critical role in the regulation of cell adhesion and barrier function. The purpose of this study was to analyze signal cascades and processes occurring subsequent to AJ disruption induced by RhoGEF17 knockdown. Primary human and immortalized rat EC were used to demonstrate that an adenoviral-mediated knockdown of RhoGEF17 resulted in cell rounding and an impairment in spheroid formation due to an enhanced proteasomal degradation of AJ components. In contrast, β-catenin degradation was impaired, which resulted in an induction of the β-catenin-target genes cyclin D1 and survivin. RhoGEF17 depletion additionally inhibited cell adhesion and sheet migration. The RhoGEF17 knockdown prevented the cells with impeded cell–cell and cell–matrix contacts from apoptosis, which was in line with a reduction in pro-caspase 3 expression and an increase in Akt phosphorylation. Nevertheless, the cells were not able to proliferate as a cell cycle block occurred. In summary, we demonstrate that a loss of RhoGEF17 disturbs cell–cell and cell–substrate interaction in EC. Moreover, it prevents the EC from cell death and blocks cell proliferation. Non-canonical β-catenin signaling and Akt activation could be identified as a potential mechanism.